DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "OpportunityAnalyzer: Sjögren's Syndrome - Opportunity Analysis and Forecast to 2024" report to their offering.
Sjögren's syndrome (SS) is a slow progressing chronic autoimmune disease, which predominantly affects middle-aged women, and is characterized by lymphocytic infiltration of the exocrine glands, mainly the lacrimal and salivary glands, resulting in reduced secretory functions and ocular and oral dryness. T
he syndrome can also cause many systemic manifestations, targeting various organs of the body. Current treatment of patients with SS is challenging, with few effective therapeutic agents available. Due to the multi-factorial nature of SS, agents are required to treat glandular symptoms of the disease - mainly salivary and lachrymal - and also any extraglandular manifestations that may arise.
However, many of the agents that are available either only treat the symptoms of the disease, are used off-label for the treatment of SS, or are considered ineffective in many patients.
The SS market is now set to enter a new phase with the potential approval of the first biologic agent for SS treatment.
Key Questions Answered
- The SS market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the SS market?
- The late-stage SS pipeline includes the biologic treatment Orencia (abatacept). Will this late-stage drug make a significant impact on the SS market? Will this drug reach peak sales by the end of the forecast period?
- The current SS market is dominated by the use of off-label therapies. How will the approval of the first biologic agent for the treatment of SS change the drug treatment landscape? What are the key drivers and barriers to market growth?
- The main driver of the expansion of the SS market will be the anticipated approval of the first biologic agent for the treatment of SS, Bristol-Myers Squibb's Orencia (abatacept).
- Growth will also be driven by an increase in the prescribing of off-label biologic therapies for the treatment of SS, such as Genentech/Biogen's Rituxan (rituximab). However, this growth will be dampened by the anticipated entry of cheaper rituximab biosimilars.
- Until the first biologic agent is approved for the treatment of SS, physicians will continue to have difficulty in gaining reimbursement for the use of off-label biologics in their patients, due to their expense and the lack of treatment guidelines to help payers in making reimbursement decisions.
- A number of randomized controlled trials evaluating biologics in SS have failed, bringing into question the design of the clinical trials. It is believed that as more robust scoring systems and an accurate disease activity index are used in SS clinical trials, studies will be more capable of providing clinically relevant information, with an increased likelihood of detecting efficacy.
- Bristol-Myers Squibb
- Chugai and Zenyaku Kogyo Co.
- Daiichi Sankyo
- Kissei Pharmaceutical
- Ono Pharmaceutical
- Santen Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/jbct8b/opportunityanalyze